Drug Trial Radar · NCT04045405
Clinical Study to Assess Safety, PK and PD Parameters of CDR132L
Last checked: Nov 19, 2026Latest source record: Jan 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
28
Actual
Start
Jun 21, 2019
Primary completion
Jan 31, 2020
Study completion Jun 26, 2020
Sponsor
- Lead sponsor
- Cardior Pharmaceuticals GmbHIndustry
- Sponsor type
- Industry
- First posted
- Aug 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I, randomized, double-blind, placebo-controlled study to assess safety, pharmacokinetics and pharmacodynamic parameters of CDR132L in patients with stable heart failure of ischemic origin (NYHA 1-3).
Conditions
- Heart Failure
Interventions
CDR132LDrug
i.v. administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events [safety and tolerability]Time frame: 4 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Richmond Pharmacology Ltd., 1A Newcomen Street, London Bridge
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.